Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 6;5:16237. doi: 10.1038/srep16237

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(A) Images of DCX+ neuronal cells differentiated from human ESCs. Cells were treated with 0.5 μm mevastatin; 3 μm kenpaullone; combination; or DMSO control during differentiation. (B) Quantification of the percentage of human ESC differentiated DCX+ neuronal cells with or without treatment. (C) Images of DCX+ neuronal cells differentiated from human iPSCs. Cells were treated with 0.5 μM mevastatin; 3 μM kenpaullone; combination; or DMSO control during differentiation. (D) Quantification of the percentage of human iPSC differentiated DCX+ neuronal cells with or without treatment. (E) Images of TH+ dopaminergic neuronal cells differentiated from human ESCs. Cells were treated with 0.5 μm mevastatin; 3 μm LY364947; combination; or DMSO control during differentiation. (F) Quantification of the percentage of human ESC differentiated TH+ neuronal cells with or without treatment. (G) Images of TH+ dopaminergic neuronal cells differentiated from human iPSCs. Cells were treated with 0.5 μM mevastatin; 3 μM LY364947; combination; or DMSO control during differentiation. (H) Quantification of the percentage of human iPSC differentiated TH+ neuronal cells with or without treatment. (I–K) Characterization of the TH+ cells differentiated from mevastatin LY364947 combination treated human PSCs (left panels, human ESCs; right panels, human iPSCs). All the TH+ cells expressed neuronal marker Tuj (I), most of them also coexpressed VMAT2 (J). All the TH+ cells also expressed midbrain floor plate marker FoxA2 (K). Example cells were pointed with arrow heads. *P < 0.05. Scale bars, 50 μm in (A–G); 20 μm in (I–K).